National Cancer Institute (nci)

This study tests a drug called Briquilimab to see if it can make stem cell transplants safer for people with GATA2 deficiency, a genetic condition that weakens the immune system and raises the risk of serious infections and blood cancers. About 7 people aged 6 to 70 will receive …

This large study tests whether a single dose of the HPV vaccine works as well as the standard two doses to prevent HPV infection, which causes most cervical cancers. About 28,000 girls aged 12–16 in Costa Rica are taking part. If one dose is effective, it could make vaccination c…

This study looks at whether giving the HPV vaccine on a different schedule (a first shot followed by a booster years later) still protects against HPV, a virus that can cause several cancers. About 200 healthy 9-11 year old girls and boys are taking part. Researchers will measure…

This early-stage trial tests a gel form of the drug endoxifen on the breast skin of 32 women scheduled for mastectomy. The goal is to see if the gel is safe and can reduce breast cancer risk. Participants apply the gel or a placebo daily for up to 4 weeks before surgery, and rese…

This study tests whether adding panitumumab to sotorasib works better than sotorasib alone for people with advanced solid tumors that have a KRAS G12C mutation. About 105 adults with cancers that have spread will be randomly assigned to one of two groups. The goal is to see if th…

This study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and is no longer responding to standard treatments. The drug works by blocking certain enzymes that cancer cells need to grow. The goal is to see if M17…

This study compares a combination of two drugs (olaparib and temozolomide) against the usual chemotherapy drugs for people with advanced uterine leiomyosarcoma that has worsened after initial treatment. The goal is to see if the new combo can shrink tumors or slow the cancer bett…

This study tests whether adding the drug pomalidomide to standard chemotherapy can improve treatment for people newly diagnosed with a specific type of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 adults will be randomly assigned to receive either …

This study tested a personalized approach to dosing the cancer drug pazopanib in 54 people with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find the dose that works best with the fewest side effects by measuring drug levels …

This study tested two different doses of the drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be removed by surgery. The goal was to see if the combination could delay cancer growth better than ipilimumab alon…

This early-stage trial tested two drugs, ibrutinib and palbociclib, together in 28 people whose mantle cell lymphoma had come back after prior treatment. The goal was to find the safest dose and see how well the combination shrinks tumors. Both drugs block enzymes that cancer cel…

This study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't responded to standard therapy. First, patients receive a virus-based drug (talimogene laherparepvec) injected directly into tumors to help the immune system recognize and att…

This study tests a drug called olaparib in people with advanced bladder or urinary tract cancers that have specific DNA repair problems. Olaparib works by blocking a protein that cancer cells need to fix their damaged DNA, which may stop tumor growth. The trial aims to see if the…

This early-phase trial tests a new drug (telaglenastat) added to standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The main goal is to find the safest dose and see if the combination helps shrink tumors. About 40 adults …

This early-stage trial tested the safety and best dose of two drugs—cyclophosphamide and veliparib—given together to people with HER2-negative breast cancer that has spread or cannot be removed by surgery. The goal was to find the right dose for future studies and to see if the c…

This study tested two different drugs, imatinib and dasatinib, in 406 people newly diagnosed with chronic phase chronic myeloid leukemia (CML). The goal was to see how well each drug reduced cancer cells in the blood. Both drugs work by blocking enzymes that help cancer grow, and…

This early-stage trial is testing two experimental drugs, veliparib and dinaciclib, in about 121 adults with advanced solid tumors that have spread and cannot be cured with standard treatments. The main goal is to find the safest and most effective dose by monitoring side effects…

This study tests a drug called MLN0128 (TAK-228) in 49 adults with advanced cancers that have TSC1 or TSC2 mutations. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the tumors shrink or disappear.

This study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific mutations in the SMO or PTCH1 genes. The drug works by blocking a growth signal that cancer cells rely on. The goal is…

This study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific RET gene change. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for many types of advanced or returning cancers, includ…

This phase III trial compares the usual immunotherapy (nivolumab and ipilimumab followed by nivolumab alone) to the same treatment plus an additional drug called cabozantinib in 1,175 patients with advanced kidney cancer that has spread. The goal is to see if adding cabozantinib …

This early-stage trial tests a drug called peposertib combined with radiation therapy for people with advanced head and neck cancer who cannot take the standard chemo drug cisplatin. The study aims to find the safest dose of peposertib and see if the combination helps control the…

This early-phase study tests the safety and best dose of the drug veliparib when given with standard chemotherapy (carboplatin and paclitaxel) in people with advanced solid tumors that also have liver or kidney problems. The goal is to find a safe dose and understand how the body…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced urothelial cancer (a type of bladder cancer) that has spread or come back. The study includes 72 adults who cannot take t…

This study compares standard chemotherapy (VAC/VI) to the same chemo plus temsirolimus in people up to age 40 with intermediate-risk rhabdomyosarcoma, a type of muscle cancer. The goal is to see if adding temsirolimus improves event-free survival and overall survival. Participant…

This study tests whether two immunotherapy drugs, ipilimumab and nivolumab, can help people with a recurrent, aggressive brain cancer (grade 4 glioma) that has many genetic mutations. The goal is to see if these drugs can shrink or control the tumor better than standard treatment…

This study planned to test a new drug called CBX-12 in people with advanced colorectal cancer that had stopped responding to standard treatments. The drug was designed to deliver a cancer-killing substance directly into tumor cells. However, the trial was withdrawn before enrolli…

This study tests whether adding an immunotherapy drug called atezolizumab to standard radiation therapy helps people with early-stage non-small cell lung cancer live longer. About 480 participants with stage I-IIA lung cancer who cannot have surgery will receive either radiation …

This study looks at whether adding the immunotherapy drug nivolumab to the usual two-drug treatment (encorafenib and cetuximab) works better at shrinking tumors in people with a specific type of advanced colorectal cancer that has a BRAF gene mutation. About 84 adults whose cance…

This early-phase trial is testing whether adding a new drug called navtemadlin to standard chemotherapy can help control acute myeloid leukemia (AML) better than chemo alone. The study involves about 24 adults with newly diagnosed AML and aims to find the safest dose and check fo…

This study tests whether adding the drug veliparib to standard chemotherapy (topotecan and carboplatin) works better than chemo alone for people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults with these ca…

This early-phase trial tests a new drug (CB-839 HCl) combined with two standard treatments (carfilzomib and dexamethasone) in 36 adults whose multiple myeloma has come back or stopped responding to prior therapy. The main goal is to find the safest dose and check for side effects…

This large phase III study enrolled 1,673 patients with high-risk melanoma that had been removed by surgery. It compared two drugs—ipilimumab and high-dose interferon alfa-2b—to see which one better prevents the cancer from returning. The goal is to find a more effective treatmen…

This early-phase trial tests a combination of a BET inhibitor (ZEN003694) with immunotherapy drugs (nivolumab and ipilimumab) in people with advanced solid tumors that no longer respond to standard treatments. The goal is to find the safest dose and see if the combo can shrink or…

This study tests whether combining copanlisib and rituximab can slow the growth of follicular lymphoma, a type of blood cancer. About 33 adults with untreated follicular lymphoma will receive the drugs through an IV over several 28-day cycles. The goal is to see how many patients…

This study was designed for people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. It aimed to compare a targeted therapy (erdafitinib) alone versus the same drug combined with an immunotherapy (atezolizumab) to see if these treatment…

This study tested a drug called nivolumab in 26 people with cervical cancer that had returned or spread. The drug helps the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the disease, but it is not a cure.

This early-phase trial tested a combination of two drugs, erlotinib and irinotecan, in 60 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked for signs …

This study tested whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have…

This study tests a drug called larotrectinib in people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug blocks a faulty protein that helps cancer grow. About 35 adults with various solid tumors or lymphomas will receive the drug to see if …

This study looks at whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before they have surgery. About 278 adults with stage II to IVA cancer will take part. The…

This study tested whether adding the experimental drug cixutumumab to standard chemotherapy (paclitaxel) helps people with advanced esophageal or stomach-junction cancer that has spread. About 94 adults whose cancer returned after first treatment took part. The goal was to see if…

This study tested two different doses of dexamethasone (a chemotherapy drug) combined with lenalidomide (an immune-boosting drug) in 452 people newly diagnosed with multiple myeloma. The goal was to see which dose worked better at shrinking tumors. If the first combination didn't…

This early-phase study tests the safety of a new gene therapy for adults with multiple myeloma that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack myeloma cells. Participants recei…

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. About 10 adults with cert…

This study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. Vorinostat works by blocking certain enzymes that cancer cells need to grow. The main goal is to see how many patients' tumors shrink or disappear, and researche…

This early-phase study tests a combination of three drugs—bortezomib, sorafenib, and decitabine—in patients with acute myeloid leukemia (AML), especially those who are older or whose cancer has returned. The main goal is to find the safest dose and understand side effects. The st…

This study tests a new combination of drugs (Dara-SVD) for people with high-risk newly diagnosed multiple myeloma. It compares this experimental treatment to the usual standard of care. The goal is to see if the new combo leads to better cancer control and fewer remaining cancer …

This phase 3 trial tests two different immunotherapy drugs—nivolumab or brentuximab vedotin—each given with standard chemotherapy for people aged 12 and older with newly diagnosed stage III or IV Hodgkin lymphoma. The goal is to see which combination better delays the cancer from…

This study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in people with HPV-positive cancers that have spread or are advanced. The goal is to find a safe dose and see if the combination boosts the immune system to fight the cancer better. Participants receive…

This study tested two immunotherapy drugs (tiragolumab and atezolizumab) plus targeted radiation for people with a type of advanced colorectal cancer called microsatellite stable (MSS) that doesn't respond well to standard immunotherapy. The trial aimed to find the right dose and…

This study tests whether adding ipatasertib to the hormone therapy megestrol acetate is more effective than megestrol acetate alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer will receive either the comb…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 529 people took part. The main goal…

This study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink or control rare cancers that have few treatment options. About 818 adults with over 50 different rare tumor types are participating. The goal is to see how many patients respond to tr…

This study tested a combination of two drugs, olaparib and cediranib, in 70 people with ovarian, fallopian tube, or peritoneal cancer that had come back after initial treatment. The goal was to see if the drug pair could slow cancer growth by blocking enzymes that cancer cells ne…

This study tests the drug afatinib in 19 patients with advanced solid tumors or lymphomas that have a specific EGFR gene mutation and have stopped responding to standard treatments. Afatinib works by blocking the mutated EGFR signal that tells cancer cells to grow. The goal is to…

This study compares the drug lenalidomide against simply watching and waiting in people with a high-risk, early form of multiple myeloma called smoldering myeloma. The goal is to see if the drug can delay the cancer from becoming active and needing stronger treatment. About 226 p…

This study tests whether the drug pazopanib can slow the growth of carcinoid tumors that are getting worse. About 171 adults with low- or intermediate-grade neuroendocrine tumors will receive either pazopanib or a placebo. The main goal is to see how long it takes for the tumors …

This study tests whether adding the experimental drug AZD1775 to standard chemotherapy (gemcitabine) can help women with ovarian, fallopian tube, or peritoneal cancer that has returned after platinum-based treatment. The drug works by blocking a protein that cancer cells use to r…

This early-phase trial tests a new drug, anetumab ravtansine, combined with immunotherapy (nivolumab, ipilimumab) and chemotherapy (gemcitabine) in people with advanced pancreatic cancer that has a specific marker (mesothelin). The goal is to find the safest dose and see if the c…

This study tests whether the drug pazopanib can delay or prevent kidney cancer from returning in people who have had surgery to remove all visible tumors. About 129 adults with advanced kidney cancer that spread to other parts of the body but was fully removed by surgery will tak…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard treatment (azacitidine and venetoclax) can help older adults with acute myeloid leukemia (AML) achieve deeper remission and lower the chance of the cancer coming back. About 60 participants who are …

This early-phase trial is testing the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The study includes up to 33 adults whose cancer has spread or cannot be removed by surgery…

This study tests three drugs—durvalumab, olaparib, and cediranib—in different combinations for people with advanced solid tumors, including ovarian, breast, lung, prostate, and colorectal cancers. The goal is to see if these combinations can shrink tumors or slow cancer growth. P…

This study tests a drug called palbociclib in people with advanced cancers that have extra copies of certain genes (CCND1, 2, or 3). The drug blocks proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 40 adults wi…

This study looks at whether adding talazoparib to atezolizumab is better than atezolizumab alone for maintenance therapy in people with a specific type of extensive-stage small cell lung cancer (SLFN11-positive). About 100 participants will receive either the combination or the s…

This study tests whether a combination of two immunotherapy drugs (relatlimab and nivolumab) works better than standard chemotherapy (lomustine) for people whose glioblastoma (a type of brain cancer) has returned after initial treatment. About 184 participants will receive either…

This study tests if the drug pembrolizumab works better than the usual treatments (high-dose interferon or ipilimumab) for people with high-risk melanoma that has been removed by surgery. About 1,300 patients took part. The goal is to see if pembrolizumab helps people live longer…

This study tests the drug selumetinib in adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink these tumors or slow their growth. Participants take selumetinib capsules twice daily and are mon…

This study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF mutations or fusions. Trametinib blocks certain proteins that help cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. The trial is no lo…

This study tests whether the drug copanlisib can shrink or stop the growth of cancers that have lost a protein called PTEN. About 22 adults with various advanced solid tumors will receive the drug. The goal is to see if blocking certain enzymes can control the disease.

This phase 2 trial tests whether adding nilotinib (a targeted therapy) to paclitaxel (a standard chemo drug) can shrink or slow advanced solid tumors that have already been treated with taxane chemotherapy and are still growing. About 40 adults with various solid cancers will rec…

This study tests a new drug combination for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The trial compares two treatments: one group gets a standard chemo drug (paclitaxel) plus bevacizumab, while t…

This study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, then donor stem cells to rebuild a healthy immune system. The trial includes 71 …

This study tested a combination of two drugs—azacitidine and gemtuzumab ozogamicin—in 133 adults aged 60 and older with untreated acute myeloid leukemia (AML). The goal was to see how well the treatment worked at putting the cancer into remission and how safe it was. Participants…

This study is for people with a certain type of stomach or gastroesophageal junction cancer that has a high number of genetic mutations (MSI-H/dMMR). It compares the immunotherapy drug atezolizumab alone versus atezolizumab combined with chemotherapy, given before and after surge…

This study looks at whether the immunotherapy drug nivolumab can help people with acute myeloid leukemia (AML) stay in remission after chemotherapy. It involves 82 adults whose cancer had shrunk or disappeared after initial treatment. The goal is to see if nivolumab can eliminate…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemoradiation helps people with limited stage small cell lung cancer live longer. About 544 participants receive either chemoradiation alone or chemoradiation plus atezolizumab. The goal is to see i…

This study tests whether adding an experimental drug called TRC102 to standard chemotherapy (cisplatin and pemetrexed) can shrink tumors or slow cancer growth in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. About 30 adults will take…

This study is for women with ovarian, fallopian tube, or peritoneal cancer that has come back and no longer responds to platinum-based chemotherapy. It tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy at keeping the…

This study tests whether a combination of two drugs, talazoparib and temozolomide, can shrink or stop the growth of rare cancers that have spread. It is for people whose cancer has not responded to standard treatments. The drugs work by damaging cancer cell DNA and blocking its r…

This early-phase trial tests a three-drug combination (tazemetostat, topotecan, and pembrolizumab) in adults whose small cell lung cancer has returned after prior treatment. The goal is to find the safest dose and see if the combo can shrink or stabilize the cancer. About 18 part…

This study tests a drug called erdafitinib in people with advanced cancers that have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from getting worse for at least 6 months…

This early-phase study tests a combination of the targeted drug ibrutinib with a chemotherapy regimen called TEDDI-R in people with primary CNS lymphoma, a rare brain cancer. The goal is to find the safest dose and see if the treatment can control the disease. About 68 adults wit…

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to their bones. The radioactive drug targets bone tumors directly, while chemotherapy works throughout the body. About 70…

This study looks at a rare, often fatal disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers want to understand how the disease works and test several experimental drug combinations, including zidovudine, valganciclovir, bortezomib…

This study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…

This study tests two drugs—olaparib and temozolomide—together in 23 people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery. The goal is to see if the combination can shrink tumors better than either drug alone. Participants receive both drugs …

This study tests if bevacizumab, a drug that blocks blood vessel growth, can help adults with recurrent respiratory papillomatosis (RRP) go longer between surgeries to remove wart-like growths in the airways. About 21 participants who need at least two surgeries per year will rec…

This study tested a treatment plan for adults aged 65 and older with a type of blood cancer called acute lymphoblastic leukemia (ALL). The treatment combined an immunotherapy drug (blinatumomab) with either standard chemotherapy or another targeted drug (dasatinib). The goal was …

This early-phase trial tests a new drug called M3814 combined with three chemotherapy drugs (MEC) in 48 adults whose acute myeloid leukemia has returned or not responded to treatment. The goal is to find the best dose and check for side effects. The study is active but no longer …

This early-phase study tests a new drug (MLN0128) combined with bevacizumab in about 50 people with recurrent glioblastoma or other advanced solid tumors. The goal is to find the safest dose and understand side effects. The drugs work by blocking tumor growth and cutting off bloo…

This study tests a combination of the chemotherapy drug paclitaxel and the targeted therapy ipatasertib in people with advanced solid tumors (cancers that have spread or can't be removed by surgery) that have specific changes in the PTEN or AKT genes. The goal is to see if adding…

This early-stage trial tests a new three-drug combination for adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard chemotherapy. The drugs include a targeted radiation therapy (lintuzumab-Ac-225), a pill that blocks cancer cell survival (venetoclax), …

This study tests a drug called elimusertib in children and young adults whose solid tumors have come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors by blocking enzymes that help cancer cells grow. About 31 participant…

This early-phase study tests the safety and best dose of the drug trametinib when given with or without whole-brain radiation for people whose cancer has spread to the brain. The goal is to see if the combination is safe and how much drug reaches the brain. Only 10 participants a…

This phase II trial tests whether a combination of three drugs—darolutamide, leuprolide acetate, and exemestane—can shrink or stabilize recurrent adult-type ovarian granulosa cell tumors. The drugs work by blocking hormones that fuel tumor growth. About 37 adults whose cancer ret…

This study tests a combination of two drugs, veliparib and topotecan, in people with solid tumors or ovarian cancer that has returned after initial treatment. The goal is to find the best dose and see how well the drugs shrink tumors. About 88 adults with advanced or recurrent ca…

This study tested two drugs, tarlatamab and sacituzumab govitecan, in people with advanced small cell lung cancer or a similar aggressive cancer outside the lungs. The goal was to see if the combination was safe and could shrink tumors. The study was withdrawn before enrolling an…

This study tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent triple-negative breast cancer from coming back. About 1,155 patients with remaining cancer after chemo will receive either pembrolizumab or a placebo. The goal is to see…

This study compares a standard chemotherapy drug (azacitidine) alone versus combined with either lenalidomide or vorinostat for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if adding a second drug improves r…

This early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or couldn't be surgically removed. The main goal was to find the safest dose and see how well patients tolerated the tre…

This study tested a drug called ibrutinib in 18 people with stage IV melanoma that had not responded to prior therapy. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The main goal was to see if the drug could shrink tumors, and researchers also looked at…

This study compares a drug called blinatumomab, which helps the immune system attack leukemia cells, to standard chemotherapy in children and young adults whose B-cell acute lymphoblastic leukemia has returned after treatment. About 669 participants are randomly assigned to recei…

This early-stage trial tested whether giving a combination of immunotherapy (atezolizumab) and chemotherapy before surgery can help shrink tumors in people with a type of lung cancer called malignant pleural mesothelioma. 28 patients with stage I-III disease that could be surgica…

This study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation, and continuing it afterward, helps people with stage III lung cancer that cannot be surgically removed live longer or keep the cancer from coming back. About 660 adults with newly diagno…

This study looks at whether adding an experimental drug (MK-2206) to standard hormone therapy (bicalutamide) can better control prostate cancer in men whose PSA levels are rising after initial treatment. About 108 men with recurrent prostate cancer will be randomly assigned to re…

This study tests whether adding the drug venetoclax to standard chemotherapy can help prevent aggressive B-cell lymphomas from coming back. About 363 adults with double-hit or double-expressor lymphoma will receive either the usual chemo or the usual chemo plus venetoclax. The go…

This study tests a drug called tazemetostat in people whose ovarian or endometrial cancer has returned after previous treatment. The goal is to see if the drug can shrink tumors or stop them from growing. About 62 participants will receive the drug, and doctors will measure how m…

This early-phase study tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the best dose and see if the combination is safe and tolerable. About 74 participants will receive the dr…

This study tests a drug called DS-8201a (trastuzumab deruxtecan) in people aged 12 to 39 with HER2-positive osteosarcoma that has returned. The drug works like a smart bomb, attaching to HER2 on cancer cells and delivering chemotherapy directly to them. The main goal is to see if…

This study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow the cancer's sp…

This study tests whether adding a third drug, venetoclax, to the standard two-drug combination of ibrutinib and obinutuzumab works better for younger patients with chronic lymphocytic leukemia (CLL) who have not yet been treated. The trial involves 720 participants and aims to se…

This study tests whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a certain type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 newly diagnosed patients will be randomly assigned to receive eit…

This study tested a combination of two drugs, olaparib and ceralasertib, in 24 adults with advanced solid tumors that have an IDH mutation, including bile duct cancer. The goal was to see if the drugs could shrink or stop the cancer from growing. While the study did not report tu…

This study tests a pill called palbociclib in people with advanced cancers that have extra copies of the CDK4 or CDK6 genes. The drug blocks signals that make cancer cells multiply. About 43 adults with solid tumors or lymphoma that haven't responded to other treatments will take…

This study tests a new drug, pevonedistat, combined with standard chemotherapy (carboplatin and paclitaxel) in people with advanced non-small cell lung cancer that has already been treated with immunotherapy. The goal is to see if this combination can shrink tumors or slow cancer…

This study tests whether adding a drug called triapine to the standard radioactive treatment Lutathera works better than Lutathera alone for people with advanced neuroendocrine tumors that have spread. About 94 adults with a specific type of these tumors will be randomly assigned…

This study tests adding vorinostat to standard chemo-immunotherapy (R-CHOP) for people with newly diagnosed advanced diffuse large B-cell lymphoma. The goal is to find the safest dose and see if it helps keep cancer from coming back. About 83 adults with stage II, III, or IV dise…

This early-phase trial studies the safety and best dose of two drugs—riluzole and sorafenib—given together to adults with advanced solid tumors or melanoma that has spread and is hard to treat. The goal is to see if the combination can slow or stop tumor growth. About 35 particip…

This study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can shrink advanced rectal cancers before surgery. It includes 31 adults with a specific genetic type of rectal cancer (MSI-H/dMMR) that has spread locally. T…

This study tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib works better than cabozantinib alone for people with advanced papillary kidney cancer that has spread. About 200 participants will receive either the combination or cabozantinib …

This early-phase trial tests the safety and best dose of combining two drugs—osimertinib and necitumumab—in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 adults with stage IV or recurrent lung cancer will take pa…

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. The goal is to shrink or eliminate the tumor while preserving the …

This study tests two drugs, darolutamide and leuprolide, in 21 people with a rare type of salivary gland cancer that has spread or come back. The drugs work by blocking hormones that help the cancer grow. The goal is to see if the combination can shrink tumors or stop them from g…

This study tests whether two targeted drugs, dabrafenib and trametinib, given after radiation therapy can help children and young adults (up to age 25) with a specific type of aggressive brain cancer called BRAF V600-mutant high-grade glioma. The drugs block proteins that help th…

This study compares three different drug combinations for people with advanced head and neck cancer that has spread or come back after prior treatment, including immunotherapy. About 430 adults will receive either standard chemotherapy plus cetuximab, chemotherapy plus bevacizuma…

This study compares two treatments for metastatic pancreatic cancer in people with inherited BRCA1 or BRCA2 mutations. One group gets olaparib alone, the other gets olaparib plus pembrolizumab. The goal is to see if the combination helps keep the cancer from growing longer. About…

This study tests whether a newer drug, z-endoxifen, works better than the standard tamoxifen for postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). About 81 women whose cancer has spread despite prior hormone therapy will be randomly assigned to one o…

This early-phase study tests a new two-drug combination (sapanisertib plus osimertinib) in about 36 people with advanced EGFR-mutant non-small cell lung cancer that has worsened after standard treatment. The main goal is to find the safest dose and understand side effects. The ap…

This early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. …

This study tests a drug called olaparib in people whose leukemia or bone marrow disorder has returned or not responded to treatment. It is for those with a specific change in the IDH gene. The goal is to see if olaparib can shrink or control the cancer by blocking enzymes that he…

This study tests whether adding veliparib to the chemotherapy drug temozolomide helps people with small cell lung cancer that has returned or stopped responding to treatment. About 97 participants will receive either the drug combo or a placebo with chemo. The goal is to see if t…

This study tests a drug called adavosertib in adults with advanced solid tumors that lack a gene called SETD2. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them from getting worse.

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy works better than chemotherapy alone for people with anal cancer that has spread. About 205 adults with inoperable or metastatic anal cancer will take part. The goal is to see if the combina…

This study tests whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with small cell lung cancer or high-grade neuroendocrine cancers. These cancers often stop responding to standard chemotherapy. The trial includes 37 adults and aims to find t…

This study tests a combination of two drugs, tazemetostat and pembrolizumab, in people with advanced bladder cancer that has spread. The goal is to find the best dose of tazemetostat and see if adding it to pembrolizumab works better than pembrolizumab alone. About 30 adults with…

This early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed. The main goal is to find the safest dose and understand side effects. About 66 adults with certain cancers…

This early-phase study tested two drugs, cediranib and selumetinib, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see how well the combination blocks tumor growth by cutting off blood supply an…

This study tested the drug afatinib in 40 adults with advanced cancers that have a specific genetic change called a HER2 mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal was to see if the drug could shrink tumors or stop them from growing…

This study tested a drug called dinaciclib in 72 people with stage IV melanoma that had spread. The drug works by blocking enzymes that help cancer cells grow. The goal was to see if it could help control the disease and improve survival.

This study tests whether adding the experimental drug PEN-866 to two standard chemotherapy drugs (vincristine and temozolomide) can help adolescents and young adults (ages 12–39) whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest …

This early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) for ovarian and related cancers that no longer respond to platinum-based treatments. The goal is to find the safest dose and see if the combination works better than chemo alone. About …

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to standard chemotherapy works better than chemotherapy plus just one immunotherapy drug for people with advanced liver cancer that can't be removed by surgery. About 88 adults with a specific …

This study tested three different three-drug combinations as the first treatment for people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best to stop the cancer from growing. A total of 349 participants were enrolle…

This study tests whether combining the drug lenalidomide with a vaccine can help people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have high-risk genetic features. Lenalidomide is designed to stop cancer growth and boost the immune…

This study tested a combination of two drugs, cediranib and olaparib, in 122 people with advanced or spreading solid tumors, including certain breast, lung, and pancreatic cancers. The goal was to see if the combo could shrink tumors by blocking enzymes that help cancer grow and …

This study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes …

This study tests whether adding the drug veliparib to standard radiation and chemotherapy can help children and young adults with a fast-growing brain tumor called high-grade glioma. The drug works by blocking a protein that helps tumor cells repair themselves, making them more s…

This study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like rhabdoid tumors or epithelioid sarcoma) have returned or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to …

This study tests whether taking a break from two targeted melanoma drugs (dabrafenib and trametinib) works as well as taking them continuously. About 280 people with advanced, inoperable BRAF-mutant melanoma will be randomly assigned to one of the two schedules. The goal is to se…

This early-stage trial tests the safety and best dose of a drug called triapine when given with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine may slow tumor growth by blocking certain enzymes, and radiation helps kill cancer cells. The stu…

This study tests a combination of three treatments—engineered natural killer (NK) cells, an immunotherapy drug (pembrolizumab), and an immune booster (N-803)—in adults with advanced stomach or head/neck cancer that has not responded to standard therapy. The goal is to see if this…

This study tests a daily pill called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatments. The drug works by blocking certain enzymes that cancer cells need to grow. The main goal is to see how many patients have their tumors shrink …

This study tests a drug called binimetinib in 53 adults with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called an NRAS mutation. The drug blocks proteins that help cancer grow. The goal is to see if it can shrink tumors or stop them from …

This early-stage study tested a combination of three drugs (lenalidomide, ibrutinib, and rituximab) in 12 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that had returned or stopped responding to previous treatments. The main goal was to find t…

This study looks at whether adding an oral drug (CC-486) to standard chemotherapy (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas live longer without their cancer returning. About 422 participants will receive either the standard tr…

This study compares two drug combinations—melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR)—in 306 newly diagnosed multiple myeloma patients who cannot undergo high-dose therapy. The goal is to see which combination better delays ca…

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose tumors worsened after prior treatment will receive either cabozantinib or a placebo. The goal is to see …

This study tested a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific change in the TSC1 or TSC2 gene. The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors and how well people t…

This study tests whether adding epoetin alfa to lenalidomide helps people with myelodysplastic syndrome (MDS) and anemia more than lenalidomide alone. About 247 adults with low- or intermediate-risk MDS and low red blood cell counts took part. The main goal was to see if the comb…

This study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the cancer. About 20 participants will rec…

This study is testing if adding a targeted drug called olaparib to standard radiation therapy works better than radiation alone for patients with inflammatory breast cancer. All participants have already had surgery and chemotherapy. The goal is to see if the drug helps prevent t…

This study tests the safety and effectiveness of avelumab, an immunotherapy drug, in people with thymoma or thymic carcinoma that has come back after platinum-based chemotherapy. About 56 adults will receive avelumab infusions every two weeks. The goal is to see if the drug can s…

This study looked at whether adding bevacizumab to osimertinib helps control EGFR-mutant lung cancer that has spread to the brain. About 5 adults with this condition took part. The goal was to see if the combination slows cancer growth better than osimertinib alone.

This study tests a risk-adapted approach for people with HIV and anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after standard treatment to help prevent the cancer from coming back. Th…

This early-phase trial is testing a combination of three drugs (copanlisib, olaparib, and durvalumab) in 39 adults with advanced solid tumors that have spread or cannot be removed. The goal is to find the safest dose and see how well the drugs work together. Participants must hav…

This study is for people with a type of slow-growing blood cancer called follicular lymphoma that has returned or stopped responding to treatment. Researchers are testing a drug called obinutuzumab, either alone or combined with other medicines like umbralisib, lenalidomide, or c…

This study tests a combination of three drugs (entinostat, PDS01ADC, and bintrafusp alfa) in adults with advanced cancers linked to HPV or certain colon cancers that haven't responded to standard treatments. The goal is to find a safe dose and see if the drugs can shrink tumors. …

This study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 245 participants received either ipilimumab alone or ipilimumab plus GM-CSF. The main goal was to see …

This study tests a drug called pomalidomide in 45 people with Kaposi sarcoma, a type of skin cancer. The drug works by stopping blood vessel growth and boosting the immune system to fight cancer cells. The goal is to see if it can shrink tumors and keep them under control.

This study tested a drug called AZD5363 in 35 adults with advanced cancers that have a specific genetic change (AKT mutation). The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is…

This phase III trial tested two different sequences of treatment for people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab + nivolumab) followed by targeted therapy (dabrafenib + trametinib), whil…

This study aimed to test the drug alrizomadlin (APG-115) in people with a genetic condition called BAP1 cancer syndrome who also have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. Howeve…

This study tests whether adding brentuximab vedotin (a drug that delivers cancer-killing substances directly to lymphoma cells) to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage …

This study tests a combination of three hormone-blocking drugs (enzalutamide, abiraterone, and standard hormone therapy) in men with newly diagnosed prostate cancer that hasn't spread. Researchers also use advanced PET/CT scans with a special tracer to see if they can better dete…

This study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) can help control recurrent or metastatic head and neck cancer better than immunotherapy alone. About 52 adults with incurable squamous cell carcinoma of the head and neck will take part…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have returned or spread and have a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 5 participants will receive t…

This early-phase trial studies whether adding copanlisib to the standard drugs fulvestrant and abemaciclib can better control hormone receptor-positive, HER2-negative breast cancer that has spread. About 24 participants with stage IV cancer will receive either the three-drug comb…

This early-phase study tests the safety and best dose of two drugs—ibrutinib and lenalidomide—given together to adults with certain types of B-cell non-Hodgkin lymphoma that have returned or not responded to prior therapy. The goal is to find a tolerable dose that can shrink or s…

This study tests whether a stem cell transplant from a matched sibling, unrelated donor, or half-matched parent can help people with DOCK8 deficiency, a genetic condition that weakens the immune system and causes severe infections. Participants receive chemotherapy and sometimes …

This study tests whether the immunotherapy drug pembrolizumab can help prevent Merkel cell carcinoma from returning after it has been surgically removed. About 280 adults with stage I–III Merkel cell cancer will either receive pembrolizumab or standard observation. The goal is to…

This study tests a pill called erdafitinib for people whose cancers have specific FGFR gene mutations or fusions. The drug blocks a faulty protein that helps cancer cells grow. About 35 adults with various advanced solid tumors will take part to see if the drug can shrink tumors …

This early-phase trial tests a personalized treatment for adults with metastatic solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. Doctors take a person's own white blood cells, modify them in a lab to better recognize and att…

This study tested a combination of two drugs, berzosertib and irinotecan, in 17 patients with advanced stomach or gastroesophageal junction cancer that had a specific genetic change (TP53 mutation) and was no longer responding to other treatments. The goal was to see if the combi…

This study looks at whether giving a lower dose of the drug cyclophosphamide after a stem cell transplant can help control blood cancers like leukemia and lymphoma with fewer side effects. About 105 people aged 15 to 65 with high-risk blood cancers will receive a transplant from …

This phase 3 trial tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer getting worse. The study included 608 adults whose breast cancer had spread or…

This early-phase study tests a combination of three drugs (alisertib, bortezomib, and rituximab) in adults with mantle cell or low-grade non-Hodgkin lymphoma that has returned or stopped responding to treatment. The main goal is to find the safest dose and check for side effects.…

This study tests whether adding the drug temsirolimus to standard risk-based treatment (surgery, chemotherapy, and possibly liver transplant) helps children with newly diagnosed hepatoblastoma. About 236 children with different stages of liver cancer are taking part. The goal is …

This large phase III trial studies whether adding the targeted drug dasatinib to standard combination chemotherapy can better control high-risk B-acute lymphoblastic leukemia (B-ALL) in nearly 6,000 children and young adults. The study focuses on patients whose cancer has genetic…

This study tested a combination of two drugs—trametinib (a targeted therapy) and docetaxel (chemotherapy)—in 60 people with advanced KRAS-mutant non-small cell lung cancer whose disease had worsened after one or two prior treatments. The goal was to see if the combination could s…

This early-phase study tested a combination of two drugs, vorinostat and azacitidine, in 18 adults with nasopharyngeal cancer or nasal NK-T cell lymphoma that had come back or spread. The main goal was to find the safest dose and understand side effects. The study is now complete…

This study tested a drug called vismodegib in 45 people with advanced chondrosarcoma, a rare bone cancer that has spread and is hard to treat. The goal was to see if the drug could shrink tumors or stop them from growing for at least 6 months. The drug works by blocking a specifi…

This study tests whether a targeted drug called selumetinib works as well as or better than standard chemotherapy (carboplatin/vincristine) for children and young adults (ages 2–21) with NF1-related low-grade gliomas. The goal is to control tumor growth and improve vision in thos…

This study is for adults with a specific type of acute lymphoblastic leukemia (ALL) that has a genetic change called BCR-ABL. The trial compares the usual treatment (steroids, a targeted drug called a TKI, and chemotherapy) with the same treatment plus an extra drug called blinat…

This study tests whether adding a drug called decitabine before standard chemotherapy can help more people with acute myeloid leukemia (AML) achieve remission. About 178 adults with AML that is not the most treatable type will receive either a low or high dose of decitabine follo…

This early-phase study tests the safety and best dose of a three-drug combination (entinostat, nivolumab, and ipilimumab) in people with advanced solid tumors or HER2-negative breast cancer that has spread or cannot be removed. The goal is to see if this approach can help control…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 143 people with advanced anal cancer that had spread and not responded to earlier treatments. The goal was to see if these drugs could shrink tumors or slow cancer growth by helping the immune system fight th…

This study tested whether taking lenalidomide (a drug that helps the immune system fight cancer) after a stem cell transplant could keep multiple myeloma from coming back longer than taking a placebo. About 460 people with active multiple myeloma took part. The goal was to see if…

This study tests an experimental drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink the tumors or stop them from growing. Participa…

This study tests a drug called AZD1775 in people with advanced cancers that have a specific genetic change (BRCA1 or BRCA2 mutation). The drug blocks a protein that cancer cells may need to grow. Researchers want to see if the drug can shrink tumors or stop them from growing. Abo…

This study tests whether the drugs olaparib and cediranib, alone or together, work better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has returned after initial treatment. About 579 women with platinum-sensitive cancer are particip…

This study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with a type of thyroid cancer that no longer responds to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this combination can shrink or co…

This phase 2 trial tests whether the immunotherapy drug nivolumab can stop or slow the growth of IDH-mutant gliomas, a type of brain tumor. The study includes 62 adults whose tumors have a high number of mutations (hypermutator phenotype) or not. Participants receive nivolumab in…

This study tested a drug called crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink tumors or stop them from growing. Only 5 patients took part, and the study is no longer recruiting…

This study is for people with a fast-growing blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It tests a strong chemotherapy combination (Hyper-CVAD plus dasatinib) and whether adding a donor stem cell transplant helps keep the cancer a…

This study tests a drug called copanlisib in people whose advanced cancer has a specific genetic change (PIK3CA mutation). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with vario…

This study tests two immunotherapy drugs, atezolizumab and tiragolumab, together in people with rare solid tumors that have spread or stopped responding to standard treatments. The goal is to see if the combination can shrink tumors and boost the body's immune attack on cancer. R…

This study tests a new combination of three drugs (tazemetostat, dabrafenib, and trametinib) in people with advanced melanoma that has a BRAF mutation and has stopped responding to standard treatment. The goal is to find the best dose and see if the combo can help control the can…

This study tests whether a mix of three immunotherapy drugs can shrink tumors in people with advanced HPV-related cancers, such as cervical, anal, and throat cancers. About 51 adults with cancer that has spread or cannot be removed will receive the drugs for up to one year. The g…

This study tests whether adding olaparib to the standard chemotherapy drug temozolomide helps control advanced pheochromocytoma and paraganglioma—rare tumors that often spread or can't be removed. About 46 adults with these cancers will be randomly assigned to receive temozolomid…

This study tests a new oral drug called alvelestat for people who develop a serious lung condition (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block a harmful enzyme that may damage the lungs. About 14 adults with chronic graft-versus-host d…

This study looked at 125 people with advanced non-small cell lung cancer that does not have a common gene mutation (EGFR). It tested two drugs, erlotinib and cabozantinib, given alone or together as a second or third treatment option. The goal was to see if the combination works …

This early-phase study tested an oral drug called triapine added to standard chemoradiation (cisplatin and radiation) for people with advanced cervical or vaginal cancer. The goal was to find the safest dose and check how well the body absorbs the drug. 21 participants were enrol…

This early-stage trial tests a combination of two immune-boosting drugs, pembrolizumab and recombinant interleukin-12, in 36 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and check for side effects.…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 adults with AML, including those whose leukemia arose from prior conditions, will rece…

This study compares three different drug combinations for people with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum chemotherapy. The drugs include a standard chemo (Doxil), an immunotherapy (atezolizumab), and a targeted therapy (bevacizumab…

This study looks at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemo for women with ovarian, fallopian tube, or peritoneal cancer that has come back or kept growing after platinum-based chemo. About 582 women took…

This study tests a three-part treatment for people with advanced solid tumors or bile duct cancers that have spread or can't be removed. It combines a targeted drug (peposertib), an immunotherapy (avelumab), and a short course of high-dose radiation. The goal is to find the safes…

This study tests whether adding an immunotherapy drug (nivolumab) to standard chemotherapy (paclitaxel) can better shrink or control a rare cancer of blood vessels called angiosarcoma. It involves 89 patients whose cancer cannot be cured by surgery or who declined surgery. Some p…

This early-stage study tested a combination of drugs (lenalidomide, dinutuximab, and sometimes isotretinoin) in 27 children and young adults with neuroblastoma that didn't respond to treatment or came back. The main goal was to find the safest dose and check side effects. Researc…

This study tests whether a very low dose of the drug apalutamide, taken for 3-4 weeks before prostate removal surgery, can lower PSA levels in men with early-stage prostate cancer. The goal is to see if such a low dose is effective enough to potentially allow men to delay or avoi…

This study tests a new drug (selinexor) added to standard chemotherapy (temozolomide) for people with a type of brain cancer called glioblastoma that has returned after initial treatment. The goal is to see if the combination is safe and works better than chemotherapy alone at sh…

This study is for children and young adults (ages 1 to 21) with advanced cancers that have come back or are not responding to treatment and have a specific change in their FGFR genes. The drug erdafitinib is given to block signals that help these cancer cells grow. The main goal …

This phase 3 trial tests whether adding bortezomib to a standard two-drug regimen (lenalidomide and dexamethasone) works better for people newly diagnosed with multiple myeloma who are not planning an immediate stem cell transplant. The study enrolled 525 participants and compare…

This study tests whether the drug atezolizumab, alone or with bevacizumab, can shrink tumors in people with a rare soft tissue cancer called alveolar soft part sarcoma that has spread or cannot be removed by surgery. Atezolizumab helps the immune system attack cancer cells, while…

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) helps people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial first finds the safest dose of cediranib, then randomly assigns patients to receive…

This study tests whether a daily pill called obeticholic acid (OCA) can safely reduce the number of polyps in the small bowel and colon of people with familial adenomatous polyposis (FAP), a rare inherited condition that greatly raises the risk of intestinal cancer. About 80 adul…

This study tests a combination of three drugs (ipilimumab, nivolumab, and brentuximab vedotin) in people with Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to find the safest dose and see how well the drugs work together to shrink tumors. Ab…

This study was designed to test whether combining two immunotherapy drugs, nivolumab and ipilimumab, could help children, teens, and young adults whose cancers had returned or stopped responding to treatment. It focused on tumors with many genetic mutations, which may respond bet…

This study tests whether adding the drug ganitumab to standard chemotherapy helps people with newly diagnosed Ewing sarcoma that has spread. About 312 participants will receive either chemo alone or chemo plus ganitumab. The goal is to see if the combination delays cancer growth …

This study tests a new combination of two drugs (tocilizumab and atezolizumab) plus precise radiation for people whose glioblastoma brain tumor has come back. The goal is to change the tumor's environment so the immune system can attack it more effectively. About 59 adults will t…

This study tests whether adding a drug called uproleselan to standard chemotherapy helps older adults with acute myeloid leukemia (AML) live longer without the cancer returning. About 267 participants receive either chemo alone or chemo plus uproleselan. The goal is to see if the…

This study tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks a protein that helps cancer cells repair themselves, while cediranib stops tumor growth by blocking certain enzymes…

This study tests whether adding a drug called veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. About 123 patients whose cancer returned after initial treatment will be randomly assigned to receive either FOLFIRI alone or FOL…

This study compares two experimental treatments—cabozantinib alone or combined with nivolumab—against standard chemotherapy for people with advanced non-squamous non-small cell lung cancer that has returned or spread. The goal is to see if these new options can slow cancer growth…

This study tests the drug crizotinib in people with advanced or hard-to-treat cancers that have a specific genetic change called MET exon 14 deletion. Crizotinib blocks signals that help cancer cells grow and spread. About 20 participants will receive the drug to see if their tum…

This phase 2 trial tests whether adding venetoclax to ASTX727 (decitabine + cedazuridine) works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related blood cancers that have too many immature cells (blasts). About 132 adults with these rare bone mar…

This study compares the accuracy of self-collected vaginal samples versus doctor-collected cervical samples for HPV testing in 750 women referred for colposcopy. The goal is to see if self-collection is a reliable alternative to traditional pelvic exams, which could make screenin…

This study compares the accuracy of HPV testing on self-collected vaginal samples versus samples collected by a doctor during a pelvic exam. About 500 women referred for colposcopy or cervical procedures will provide both types of samples. The goal is to see if self-collection is…

This study tests a radioactive tracer called 18F-DCFPyL to see if it can better find prostate cancer that has spread or come back after treatment. About 360 men with high-risk newly diagnosed or recurrent prostate cancer will get a PET/CT scan using this tracer. The goal is to im…

This study tests whether a new radioactive tracer called 18F-DCFPyL can better detect prostate cancer that has spread compared to a standard tracer. About 96 adults with metastatic prostate cancer will receive both types of PET/CT scans. Researchers will check how accurate the ne…

This study tests whether a daily broccoli seed and sprout extract can help firefighters clear cancer-causing chemicals from their bodies. Firefighters are often exposed to harmful substances like benzene from smoke and fires. The trial involves 72 firefighters who take either the…

This study tests whether just one dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either a single HPV shot or a placebo to see if it reduces persistent HPV infections, which can lead to cancer. If s…

This study tests whether metformin, a drug used for diabetes, can prevent oral cancer in people with precancerous mouth lesions (leukoplakia or erythroplakia). About 26 participants took metformin to see if their lesions shrank or disappeared. The goal is to stop these lesions fr…

This study tests a combination of two experimental vaccines (Tri-Ad5 and N-803) to see if they can prevent colon cancer and other cancers in people with Lynch syndrome, a genetic condition that raises cancer risk. The vaccines train the immune system to recognize and destroy prec…

This study looks at whether taking aspirin on an intermittent schedule can help prevent colorectal cancer in people who have had colorectal adenomas (precancerous growths). The trial involves 81 participants and measures changes in cell growth and death markers in the colon linin…

This study tests if a type of talk therapy called acceptance and commitment therapy (ACT) can help adults with sickle cell disease who have trouble sleeping. Participants meet with a coach over video for 8 weeks and wear a wrist device to track sleep. The goal is to see if the th…

This early-phase trial is testing the safety and best dose of a drug called berzosertib when given together with whole brain radiation therapy. It includes 15 adults with lung cancer that has spread to the brain. The goal is to find out if adding the drug to radiation is safe and…

This research study collects tissue, blood, and other samples from up to 2,400 people diagnosed with certain cancers at a young age. The goal is to find genetic changes that may explain why these cancers occur early, especially in different racial and ethnic groups. Participants …

This study was designed to measure how well the healthcare system meets the needs of adolescents and young adults (ages 12-39) living with advanced or recurrent cancer. Researchers planned to survey patients, caregivers, and clinicians about emotional, spiritual, and communicatio…

This study screens the genes of people with early-stage non-small cell lung cancer (stages IB to IIIA) that has been or will be removed by surgery. The goal is to find specific genetic changes in tumors so doctors can choose the best targeted treatments for each patient. About 8,…

This study looks at whether a special PET/CT scan, done before prostate removal surgery, can predict if prostate cancer will come back. About 175 men with high-risk prostate cancer will get the scan and then have surgery. Researchers will follow them for up to 5 years to see how …

This study follows 259 people with NF1, a genetic condition that raises the risk of tumors, over up to 10 years. Researchers track tumor growth, quality of life, and other health changes through regular check-ups, scans, and tests. The goal is to better understand how NF1 affects…

This study gathers medical information from up to 10,000 cancer patients who receive standard (non-experimental) treatments at the National Cancer Institute. It is designed for patients who are not in a research trial but need specialized care or follow-up. The goal is to build a…

This study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) and compares them to unvaccinated women. Researchers want to see how long the vaccine protects against cervical and other cancers, and whether it might lead to more lesions from other…

This study aims to find genetic changes linked to chordoma, a rare bone cancer. Researchers will collect saliva and medical history from up to 188 people in the U.S. or Canada who have chordoma and no family history of it. No treatment is given; the goal is to better understand w…

This study collects blood and urine samples from 1,000 adults who are receiving radiation therapy for cancer. Researchers want to learn how radiation affects genes in white blood cells, damages red blood cells, and changes hormone levels. Samples are taken before, during, and aft…

This early-stage trial looks at how the drug DS-8201a affects tumors in 62 adults with advanced HER2-positive cancers that have spread or cannot be removed. Researchers take small tumor samples before and after treatment to measure changes in proteins and immune cells. The goal i…

This study does not provide any new treatment. It follows up to 1,000 adults who previously received CAR T-cell gene therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects through blood tests, clinic visits, and yearly phone calls f…

This study looks at whether a high-fiber, plant-based diet and regular exercise can change the gut microbiome in adults with melanoma who are receiving immunotherapy. Participants are split into two groups: one follows a specific diet and exercise plan, while the other gets gener…

This study looks at people and families who have a high risk of cancer to learn about genetic and environmental factors that may increase that risk. Over 5,200 participants are followed over time through questionnaires, medical records, and optional genetic testing. No experiment…

This study looks at whether a genetic test called the Genomic Prostate Score (GPS) can help doctors better decide which men with low- or intermediate-risk prostate cancer are good candidates for focal therapy—a treatment that targets only the cancerous part of the prostate. Resea…

This study collects leftover tissue and blood samples from people with known or suspected cancer who are already scheduled for surgery or biopsy. Researchers will compare cancerous and normal tissues to find differences that could lead to new treatments. About 1,200 adults aged 1…

This early-phase trial studies how the drug triapine affects uterine serous cancer cells in 12 women scheduled for hysterectomy. Participants receive one dose of triapine before surgery, and researchers compare tumor samples taken before and after the drug to see if it slows canc…

This study collects blood, urine, and tumor samples from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a tissue repository for future research into DNA changes that drive these cancers. Participants give samples during rou…

This study looks back at the medical records of 232 adults with cancer who took the immunotherapy drug M7824. The goal is to make a complete list of all side effects caused by the drug. By understanding these side effects better, doctors hope to prevent or reduce them in future c…

This study does not offer new treatment. Instead, it follows about 1,150 people who previously received experimental cell or gene therapy for cancers like melanoma or neuroendocrine tumors. Participants will have yearly physical exams and blood tests for up to 15 years so doctors…

This study looks at people and families who may have a higher chance of getting blood or lymph node cancers, like leukemia or lymphoma. Researchers want to learn what causes these cancers by studying genes, environment, and medical history. Participants fill out questionnaires, g…

This study collects blood, cheek cells, semen, urine, or nail clippings from up to 1,200 healthy adult volunteers at NCI-Frederick. The samples are used for lab research only, such as genetic studies, immune tests, and drug development. Donors are paid for their time and are not …

This study gathers white blood cells and tumor samples from up to 7,000 cancer patients and healthy volunteers to help scientists grow powerful anti-cancer cells in the lab. The cells are used to create experimental treatments for cancers like melanoma, lung, and breast cancer. P…

This study collects blood samples from people who have unexpected or severe side effects from drugs they are taking in other NIH trials. The goal is to measure drug levels in the blood to better understand why side effects happen in some people but not others. Up to 100 participa…